logo-loader
Motif Bio PLC

Motif Bio PLC requests meeting with US regulator to discuss trial design

It has made the request after being encouraged by the US Food & Drug Administration to carry out further work on flagship drug iclaprim

FDA graphic
A follow-up study could be the key to gaining marketing approval for the company's antibiotic

Motif Bio PLC (LON:MTFB) has requested a second meeting with the US drug regulator as part of its bid to win marketing approval for its antibiotic, iclaprim.

The company has been asked by the Food & Drug Administration to perform a further clinical trial before it signs off the drug.

Motif therefore wants to arrange what’s called a Type-B meeting with the watchdog to discuss just which types of patient will take part in the new study along with its design.

It typically takes around 60 days from the time of request to schedule a face to face of this kind.

Along with the request, the company has also submitted an information package.

Motif chief executive Graham Lumsden said: “As we continue our discussions with potential US commercial partners and evaluate potential funding options for the iclaprim clinical programme, we expect to gain greater clarity from the Agency during the Type-B meeting on the pathway forward for iclaprim."

The FDA in an earlier discussion encouraged Motif to carry out a further trial to allay concerns over liver toxicity, which emerged following the submission of trial data from two phase III assessments of the drug.

Quick facts: Motif Bio PLC

Price: £0.02

Market: AIM
Market Cap: £8.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

on 19/8/19

2 min read